The use of PSA (prostate-specific antigen) for its diagnostic utility in prostate cancer is a subject of discussion;
however, due to its specificity to the prostate tissue, PSA remains a potential immunotherapy target. We developed a
PSA-recombinant viral vector, adenovirus5-PSA (Ad5-PSA) that generated vigorous PSA-specific immune and antitumor
responses in a prostate cancer mouse model. Using Ad5-PSA vaccine we successfully completed a Phase I clinical study
and are conducting a Phase II trial. In this review, we summarize the clinical development of this Ad5-PSA vaccine as an
immunotherapeutic agent and its potential utility for the treatment of prostate cancer.
Keywords: Ad5-PSA vaccine, prostate cancer, immunotherapy
Rights & PermissionsPrintExport